On February 17, 2015, a motion for an extension of a pending deadline was filed in the bankruptcy case of Savient Pharmaceuticals, Inc. and its affiliates.
The filing was assigned docket number 840 and is described on the court’s official docket as follows:
Second Motion to Extend /Second Motion of the Liquidating Trust for Order Extending the Claims Objection Deadline Under the Chapter 11 Plan By Which the Liquidating Trust May Object to Claims Filed by SPI Liquidating Trust. Hearing scheduled for 3/17/2015 at 11:30 AM at US Bankruptcy Court, 824 Market St., 5th Fl., Courtroom #4, Wilmington, Delaware. Objections due by 3/3/2015. (Attachments: # (1) Notice # (2) Proposed Form of Order # (3) Certificate of Service and Service List) (Keane, Peter)
Savient Pharmaceuticals, Inc. filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on October 14, 2013. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 13-12680. The bankruptcy case is currently assigned to United States Bankruptcy Judge Mary Walrath. The law firm of Skadden, Arps, Slate, Meagher & Flom LLP is acting as lead bankruptcy counsel to Savient Pharmaceuticals, Inc. in the bankruptcy case.